Nara
← Intervention Library

Experimental and investigational

MOTS-c

A mitochondrial-derived peptide studied for metabolic signalling.

Nara’s current positionClinical-trial only
Evidence briefing

Strongest directness: Other animal evidence. Last reviewed 2026-08-12.

Nara’s evidence view

Clinical-trial context only

PreliminaryNon-canine preclinical evidenceVery low confidence

The claim we’re evaluating

Exogenous synthetic MOTS-c improves clinically meaningful metabolic or physical-function outcomes in dogs.

Nara’s interpretation

MOTS-c is a credible signaling-biology research target with reproducible-looking metabolic and physical-performance effects in several mouse experiments, but that is not yet canine therapeutic evidence. Nara should distinguish endogenous MOTS-c biology from administration of a synthetic peptide and should not describe rodent metabolic or exercise findings as demonstrated canine healthspan benefit. At present, exogenous MOTS-c belongs in legitimate research rather than routine owner-directed use.

This is an umbrella assessment. The evidence differs materially depending on the outcome and the specific form of the intervention, so Nara evaluates those narrower claims separately.

Personalized

What this means for your dog.

Loading your dog’s context…

Evidence briefing

What Nara knows now.

A bounded position while the full claim-level dossier is still being completed.

What is known

MOTS-c is a mitochondrial-derived signaling peptide, and controlled mouse studies report effects on insulin resistance, diet-induced obesity, skeletal-muscle metabolism, exercise performance, and late-life physical capacity. Human work in the key exercise paper measured changes in endogenous MOTS-c after exercise rather than demonstrating benefit from administering MOTS-c to people. No peer-reviewed canine intervention study was identified in the targeted search. FDA's 2026 evidence review likewise found no human administration studies and concluded that effectiveness evidence for nominated metabolic, musculoskeletal, and longevity uses was confined to in-vitro and rodent models, with major pharmacology and safety gaps.

What is not known

No peer-reviewed canine administration or clinical-outcome study was identified. The strongest intervention evidence is from mice rather than dogs or humans. Human exercise-associated increases in endogenous MOTS-c are observational physiology and are not evidence that exogenous synthetic MOTS-c improves outcomes. Mouse findings span several outcomes and regimens and should not be collapsed into one claim of general anti-aging efficacy. FDA's review identified missing dose-response information for important preclinical effects and uncertainty regarding the peptide's molecular targets. Human exposure, clinical pharmacokinetics, immunogenicity, chronic toxicity, reproductive toxicity, carcinogenicity, and long-term safety remain inadequately characterized.

Current position

MOTS-c is a credible signaling-biology research target with reproducible-looking metabolic and physical-performance effects in several mouse experiments, but that is not yet canine therapeutic evidence. Nara should distinguish endogenous MOTS-c biology from administration of a synthetic peptide and should not describe rodent metabolic or exercise findings as demonstrated canine healthspan benefit. At present, exogenous MOTS-c belongs in legitimate research rather than routine owner-directed use.

MOTS-c is a mitochondrial-derived signaling peptide, and controlled mouse studies report effects on insulin resistance, diet-induced obesity, skeletal-muscle metabolism, exercise performance, and late-life physical capacity. Human work in the key exercise paper measured changes in endogenous MOTS-c after exercise rather than demonstrating benefit from administering MOTS-c to people. No peer-reviewed canine intervention study was identified in the targeted search. FDA's 2026 evidence review likewise found no human administration studies and concluded that effectiveness evidence for nominated metabolic, musculoskeletal, and longevity uses was confined to in-vitro and rodent models, with major pharmacology and safety gaps.